Valmet's Interim Review January-September 2025 Shows Strong Orders Growth and Stable Performance Amid Market Challenges

Valmet Oyj reported stable net sales of EUR 1,295 million for Q3 2025, matching the previous year despite global market uncertainties. Orders received grew organically by 7%, reaching EUR 1,083 million, while comparable EBITA increased slightly by 2% to EUR 159 million with an improved EBITA margin of 12.3%. Earnings per share rose 26% to EUR 0.46, driven by lower SG&A costs. For the first nine months of 2025, orders surged 17% with organic growth of 18%, although net sales declined 3% to EUR 3,720 million. Comparable EBITA stayed steady at EUR 423 million. Valmet reaffirmed 2025 guidance, anticipating net sales and comparable EBITA to remain on par with 2024 levels. The company expects stable market conditions in process performance solutions but foresees challenges and potential softness in the biomaterial solutions segment due to global economic uncertainties.